Study for Prevention of Cervical Cancer in Spain
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorClinica Universidad de Navarra, Universidad de Navarra
About this trial
The REVIVE study aims to analyze the current status of Human Papillomavirus (HPV) vaccination programs and cervical cancer screening strategies in Spain. Its objective is to gain a comprehensive understanding of the effectiveness of these preventive measures, as well as to identify the main barriers to access and the existing inequalities in care. The study will also examine the impact of misinformation on population engagement and on the overall equity of the prevention system.
Despite significant advances in both vaccination and screening efforts, cervical cancer remains a major public health concern in Spain. In 2024 alone, 2,259 new cases were diagnosed, that incidence has remained relatively stable in recent years, even decades. Mortality rates have also shown little change, with over 600 deaths annually, totaling nearly 10,000 in the last 15 years.
To address this, the study plans to include approximately 200 patients diagnosed with cervical cancer in Spain between 2019 and 2024. It is a retrospective, observational, and non-interventional study. Data will be collected from existing medical records and supplemented with a specific questionnaire administered to the participating patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Female patients diagnosed with squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix.
Diagnosis established between 2019 and 2024.
Disqualifiers
Patients aged below 18 years at diagnosis.
Diagnosis of other cervical cancer histologies (e.g., neuroendocrine tumors, sarcoma, lymphoma).
Patents with significant cognitive impairment precluding informed consent for data utilization, where applicable.
Patients with incomplete medical records relevant to the study variables.
Trial population
Female patients diagnosed with squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma of the uterine cervix.
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
Evaluate the effectiveness of current Human Papillomavirus (HPV) vaccination and screening programs in reducing cervical cancer incidence in Spain.
Biological/VaccineData will be collected from existing medical records and supplemented with a specific questionnaire administered to the participating patients.
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Prevalence of HPV vaccination and cervical cancer screening among patients diagnosed with cervical cancer in Spain
Proportion of individuals diagnosed with cervical cancer who have previously received the HPV vaccine and/or undergone cervical cancer screening prior to their cervical cancer diagnosis. The objective is to assess the effectiveness of national prevention strategies, identify gaps in vaccine and screening coverage, and understand potential barriers to early detection and vaccination.
Time frame
2019-2024Secondary outcomes
1
Percentage of HPV vaccination and screening coverage by region and demographic factors
This objective aims to determine the proportion of individuals who have received HPV vaccination and/or undergone cervical cancer screening, stratified by geographic region and key demographic factors such as age and ethnicity. The goal is to identify disparities in preventive healthcare access.
Time frame
2019-20242
Association between misinformation and socioeconomic factors and the rate of HPV vaccination and screening
This objective seeks to evaluate how misinformation and socioeconomic factors (income level, education, employment status, and healthcare access) influence the rates of HPV vaccination and participation in cervical cancer screening programs.
Time frame
2019-20243
Reported frequency and nature of barriers to accessing to HPV vaccination and cervical cancer screening
This objective aims to identify and categorize the most commonly reported barriers that individuals face when trying to access to HPV vaccination and screening programs.
Time frame
2019-2014Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: